Basilea Pharmaceutica AG
SWF:BSLN ISIN:CH0011432447
Basilea Pharmaceutica AG (SWF:BSLN) is a Switzerland-based research and development biopharmaceutical Company. The Company focuses its activities on the areas of antibacterial, antifungal and oncology agents to fight drug resistance and on the development of dermatology drugs. The Company's late-stage product portfolio comprises novel treatments for resistant bacterial infections, systemic fungal infections, and severe skin diseases. The Company's portfolio includes two commercialized drugs, alitretinoin and ceftobiprole, one investigational drug, isavuconazole, in phase III, as well as substantial early-state programs.
View in Other Languages
News
Basilea Pharmaceutica AG (BPMUF.PK) Basel, Switzerland, July 31, 2008 - Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new oral therapy for severe refractory Chronic Hand Eczema (CHE), was recommended for regulatory approval under the European decentralized procedure and will become the first authorized treatment for this chronic disabling disease.
Basilea Pharmaceutica AG (BPMUF.PK) Basel, Switzerland, July 25, 2008 - Basilea Pharmaceutica Ltd. (SWX:BSLN) announces its 2008 interim financial results - Basilea prepares to commercialize its two products currently under regulatory review.
Basilea Pharmaceutica AG (BPMUF.PK) Basel, Switzerland, June 30, 2008 - Basilea Pharmaceutica Ltd. announces that ceftobiprole (ZEFTERA(TM)), the first-in-class anti-MRSA broad-spectrum cephalosporin, has obtained regulatory approval from Health Canada authorizing the marketing of ceftobiprole for the treatment of complicated skin and soft tissue infections including diabetic foot infections. In addition, Basilea announces further organizational changes in preparation of product commercialization.
###
49,598 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 40) (Last 30 Days: 114) (Since Published: 11930)
